Baird initiated coverage of Haemonetics (HAE) with an Outperform rating and $87 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics participates in a conference call with JPMorgan
- Haemonetics Reports Balanced Earnings with Growth and Challenges
- Haemonetics price target lowered to $105 from $115 at Raymond James
- Haemonetics Reports Mixed Fiscal 2025 Results
- Haemonetics: Buy Rating Affirmed Amid Strong Q4 Performance and Margin Improvements